Stock Taper
SCREENER COMPARE ANY 2 STOCKS
FULC
FULCRUM THERAPEUTICS, INC.
NASDAQ
$3.85
▲ UP 0.26% (0.01)

KEY STATISTICS

Market Cap$293.36 M
52w High$15.74
52w Low$2.83
Dividend Yield—
Frequency—
P/E-3.56
Volume1.00M
Shares Out.76.30M

COMPANY

LEADERSHIP

Alexander C. Sapir
CHIEF EXECUTIVE
Alexander C. Sapir

COMPENSATION 2026

Salary$650,000
Stock Awards$0
Incentive Plan Pay$411,200
All Other Comp.$138,158
Total$3,251,490

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 18, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
9

PRICE TARGET

Target High$4.00
Target Low$3.00
Target Median$4.00
Target Consensus$3.60

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.—
OCT
29
THU

PRICE

$3.85 ▲ UP 0.26% (+$0.01)
$3.81$3.83$3.849:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.85

About Fulcrum Therapeutics, Inc.

https://www.fulcrumtx.com ↗

Fulcrum Therapeutics, Inc. is a Cambridge-based clinical-stage biopharma developing treatments for genetically defined diseases, including muscular dystrophy, sickle cell, and cardiomyopathies, through innovative drug discovery and strategic colla...

INDUSTRY

Biotechnology

A PRODUCT FULCRUM THERAPEUTICS, INC. IS KNOWN FOR

Losmapimod
Losmapimod

Losmapimod is an investigational oral drug for FSHD, Fulcrum's leading candidate with FDA Fast Track and Orphan Drug designations, supported by a major Sanofi collaboration for global development and commercialization.

COMPETITORS

COMPETITOR
ARWR COMPARE
DYN COMPARE
IONS COMPARE
RNA COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
82
LISTED HERE
15
RANKED BY POSITION SIZE
VTI
0.00% · 2.1M
IWM
0.01% · 1.5M
XPH
0.71% · 1.2M
FESM
0.03% · 487.0K
SCHA
0.00% · 226.4K
DFMC
0.01% · 176.2K
PINK
0.16% · 161.8K
AVSC
0.02% · 141.4K
SBIO
0.14% · 89.1K
PRFZ
0.01% · 82.0K
XRSG.L
0.01% · 48.8K
PILL
0.48% · 29.0K
RSSL
0.01% · 28.2K
BIB
0.01% · 2.4K
RESM
0.01% · 161

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.51%
HOLDERS
224
TOP 12 OF 224 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
10.2M sh · $94.11M
Suvretta Capital Management, LLC
6.6M sh · $50.32M
Blackrock, Inc.
5.4M sh · $41.35M
Tcg Crossover Management, LLC
5.3M sh · $40.27M
Blackrock Inc.
4.8M sh · $29.75M
Nantahala Capital Management, LLC
4.7M sh · $42.97M
Vanguard Group Inc
3.6M sh · $40.26M
Braidwell LP
3.1M sh · $24.04M
Adage Capital Partners Gp, L.L.C.
2.4M sh · $22.37M
Point72 Asset Management, L.P.
2.4M sh · $27.12M
Siren, L.L.C.
2.4M sh · $18.02M
First Turn Management, LLC
2.3M sh · $17.3M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score3

INSIDER TRADES

★
10 PERCENT OWNER
TANG KEVIN
Purchase · 50.9K shares
2026-07-17
★
10 PERCENT OWNER
TANG KEVIN
Purchase · 116.7K shares
2026-07-16
★
10 PERCENT OWNER
TANG KEVIN
Purchase · 76.0K shares
2026-07-14
★
10 PERCENT OWNER
TANG KEVIN
Purchase · 53.7K shares
2026-07-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
UNDERWEIGHT 2
HOLD 2
NEUTRAL 1
MARKET PERFORM 1
UNDERPERFORM 1
OVERWEIGHT 1
SECTOR PERFORM 1
9 GRADES IN THE LAST 12 MONTHS
JP Morgan UNDERWEIGHT HC Wainwright & Co. NEUTRAL Truist Securities HOLD Leerink Partners MARKET PERFORM Piper Sandler UNDERWEIGHT Stifel HOLD B of A Securities UNDERPERFORM Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
OMER$19.11COMPARE
LXRX$2.23COMPARE
NGNE$38.63COMPARE
OCGN$1.34COMPARE
CMPX$2.40COMPARE
BCYC$4.28COMPARE
NMRA$1.32COMPARE
ADCT$1.35COMPARE